PT-141 and Kisspeptin are two distinct peptides under research for sexual health—one acts on melanocortin receptors in the brain, the other modulates the HPG axis upstream of testosterone and estrogen. Neither is FDA-approved as a compounded medication; both require evaluation by a licensed provider before use.
What Is PT-141 (Bremelanotide)?
PT-141, generic name bremelanotide, is a synthetic melanocortin receptor agonist derived from alpha-MSH. A branded intranasal form (Vyleesi) carries FDA approval for premenopausal hypoactive sexual desire disorder (HSDD) in women. Compounded PT-141 is not FDA-approved and is prepared under federal compounding regulations. PT-141 acts centrally—binding MC3R and MC4R receptors in the hypothalamus—without directly affecting vascular function, distinguishing it mechanistically from PDE5 inhibitors like sildenafil.
What Is Kisspeptin?
Kisspeptin is an endogenous neuropeptide encoded by the KISS1 gene, acting on KISS1R receptors in the hypothalamus to stimulate GnRH pulsatility. GnRH drives LH and FSH release, which governs testosterone and estrogen production. Compounded kisspeptin is not FDA-approved and is prepared under federal compounding regulations. Research at Imperial College London has explored kisspeptin's role in sexual cognition and motivation beyond its well-established reproductive endocrine function.
PT-141 vs Kisspeptin: Head-to-Head Comparison
| Feature | PT-141 (Bremelanotide) | Kisspeptin |
|---|---|---|
| Primary receptor | MC3R, MC4R (melanocortin) | KISS1R (GPR54) |
| Mechanism | Central melanocortin activation | HPG axis stimulation via GnRH |
| Primary effect | Sexual desire and arousal (both sexes) | Gonadotropin release → endogenous sex hormone increase |
| FDA approval | Branded Vyleesi (women, intranasal); compounded: not approved | No approval; compounded: not approved |
| Clinical evidence | Multiple RCTs including RECONNECT trial (PubMed 31599840) | Phase I/II studies in women (PubMed 36287566) and men (PubMed 36735255) |
| Typical administration | Subcutaneous injection or intranasal | IV (research setting) or subcutaneous (compounded) |
| Onset | 45–90 minutes pre-activity | Hours to days (upstream hormonal effect) |
| Who may benefit most | Patients with desire-phase HSDD or low libido and intact HPG axis | Patients with hypogonadotropic hypogonadism or suppressed GnRH pulsatility |
How PT-141 Works
PT-141 activates melanocortin 3 and 4 receptors concentrated in the paraventricular nucleus of the hypothalamus. This central activation triggers dopaminergic and oxytocinergic pathways associated with motivated sexual behavior, producing desire and arousal effects independent of genital blood flow mechanics. The RECONNECT trials demonstrated statistically significant improvements in satisfying sexual events and sexual distress scores in premenopausal women with HSDD. Nausea at higher doses is the most commonly reported adverse effect.
How Kisspeptin Works
Kisspeptin neurons in the arcuate and anteroventral periventricular nuclei act as a master upstream switch for reproductive neuroendocrinology. KISS1R agonism increases GnRH pulse frequency, driving LH and FSH surges that elevate endogenous testosterone (men) and estradiol (women). Imperial College research demonstrated kisspeptin infusion increased activation of sexual and emotional brain regions on fMRI and improved sexual motivation scores in both men and women with low desire states, independently of direct melanocortin pathway activation.
Which Peptide to Consider
PT-141 is oriented toward on-demand desire enhancement—patients who have adequate baseline hormone levels but struggle with desire-phase responsiveness. Kisspeptin is more relevant for patients whose sexual dysfunction is rooted in suppressed HPG axis activity, low gonadotropins, or functional hypogonadism. These are not interchangeable therapies, and the appropriate peptide depends on a complete hormonal and clinical evaluation.
Both require a licensed provider assessment before any compounded formulation is approved. You can begin an asynchronous evaluation at TelosRX's peptide program. Approval is subject to evaluation by a licensed provider.
Related reading: Peptides for Libido: PT-141, Kisspeptin & Research Guide | Kisspeptin Peptide Hormone Research
Frequently Asked Questions
Is PT-141 the same as Vyleesi?
Vyleesi (bremelanotide) is the FDA-approved branded intranasal form of PT-141 for premenopausal women with HSDD. Compounded PT-141 is a different preparation—not FDA-approved—made under federal compounding regulations. Approval for compounded use is subject to provider evaluation.
Can men use PT-141?
PT-141 has been studied in men with erectile dysfunction and low desire in research settings. The FDA approval (as Vyleesi) is limited to premenopausal women, but provider evaluation may consider compounded use in male patients based on individual clinical factors.
Does kisspeptin increase testosterone?
Kisspeptin stimulates GnRH, which drives LH release from the pituitary, which in turn stimulates testicular testosterone production. Research in men demonstrated increases in LH pulse frequency and testosterone levels during kisspeptin administration, though sustained effects require ongoing dosing as part of a structured protocol.
Can PT-141 and kisspeptin be used together?
These peptides act through different receptor systems, so concurrent use is not inherently contraindicated, but no RCTs have evaluated combination protocols. Any multi-peptide protocol requires individualized provider assessment and is subject to approval by a licensed clinician.
How long does PT-141 last?
The desire-enhancing effects of PT-141 typically onset 45–90 minutes after subcutaneous administration and may last 6–12 hours. Individual variation exists. Nausea is the most commonly reported side effect, particularly at higher doses.
Is kisspeptin available as a compounded peptide?
Compounded kisspeptin formulations exist in telehealth settings. These are not FDA-approved and are prepared under federal compounding regulations. Approval for use is subject to evaluation by a licensed provider, and approval is not guaranteed.
How do I know which peptide is right for me?
Determining the appropriate peptide requires clinical evaluation—including hormonal labs, a review of desire versus arousal versus erection dysfunction patterns, and a thorough health history. TelosRX's asynchronous telehealth evaluation allows a licensed provider to assess these factors without a synchronous appointment.
Start your private evaluation at TelosRX.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.